Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $28,021.00 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 700 shares of the firm’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $40.03, for a total value of $28,021.00. Following the completion of the transaction, the chief executive officer owned 39,974 shares in the company, valued at $1,600,159.22. The trade was a 1.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Monday, October 20th, Jack Bendheim sold 16,075 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.38, for a total value of $649,108.50.
• On Thursday, September 18th, Jack Bendheim sold 7,022 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.26, for a total value of $282,705.72.
• On Wednesday, September 10th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.29, for a total value of $145,340.80.
• On Tuesday, September 9th, Jack Bendheim sold 14,080 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.33, for a total value of $567,846.40.

Phibro Animal Health Stock Up 2.1%

Shares of PAHC opened at $41.05 on Friday. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $42.32. The company has a market capitalization of $1.66 billion, a PE ratio of 34.79, a price-to-earnings-growth ratio of 1.21 and a beta of 0.83. The stock has a fifty day simple moving average of $37.65 and a two-hundred day simple moving average of $28.89. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.05. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The business had revenue of $378.70 million during the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. As a group, equities analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd were paid a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, September 3rd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. Phibro Animal Health’s dividend payout ratio (DPR) is 40.68%.

Institutional Trading of Phibro Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Cardinal Capital Management increased its position in shares of Phibro Animal Health by 2.4% during the 3rd quarter. Cardinal Capital Management now owns 98,975 shares of the company’s stock worth $4,005,000 after purchasing an additional 2,336 shares during the last quarter. SG Americas Securities LLC purchased a new position in Phibro Animal Health during the 3rd quarter valued at about $434,000. Allspring Global Investments Holdings LLC purchased a new position in Phibro Animal Health during the 3rd quarter valued at about $8,931,000. Capricorn Fund Managers Ltd purchased a new position in Phibro Animal Health during the 3rd quarter valued at about $10,233,000. Finally, Inspire Investing LLC purchased a new position in Phibro Animal Health during the 3rd quarter valued at about $1,064,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PAHC has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Phibro Animal Health in a research note on Tuesday, October 14th. Morgan Stanley set a $34.00 target price on Phibro Animal Health in a research note on Thursday, August 28th. Bank of America raised their target price on Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a research note on Friday, August 29th. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 29th. Finally, JPMorgan Chase & Co. raised Phibro Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $25.00 to $35.00 in a research report on Monday, July 7th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.40.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.